Judy George is a Deputy Managing Editor at ABC Network News. She specializes in medicine and healthcare, covering topics such as aging and longevity, diet and nutrition, mental health care, and consumer health. Judy's work has been featured in prominent outlets including Knowledia, Joe Miller for US Senate, MSN, and MedPage Today.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Judy George's coverage mainly focuses on healthcare, pharmaceuticals, and scientific research. She frequently cites data and reports on government announcements related to health topics. Therefore, she is likely to be responsive to pitches that offer access to new or exclusive data in the healthcare and pharmaceutical sector. Additionally, Judy may be interested in expert analysis or commentary on recent government announcements concerning health-related issues.
Given her extensive coverage of neurological conditions such as dementia and chronic pain, sources with expertise in these areas are likely to appeal to her. If you have insights into innovative treatments or emerging trends within the healthcare industry, particularly those related to neurology or chronic pain management, Judy would likely find them valuable for her reporting.
This information evolves through artificial intelligence and human feedback. Improve this profile .
BCG vaccine altered immune responses and modified amyloid-beta, study shows
By: Judy George
News and commentary from the world of neurology and neuroscience
By: Judy George
Levacetylleucine succeeds in phase III trial of adults and kids with ataxia-telangiectasia
Levacetylleucine (Aqneursa) improved neurologic symptoms and functioning in adults and children with ataxia-telangiectasia in a phase III, randomized, crossover trial.
By: Judy George
What is transient global amnesia? Couric's recent health scare explained
Judy George Journalist Katie Couric recently shared her experience of sudden memory loss that persisted for several hours during a recent trip to Colorado.
Judy George Modifiable dementia risk factors varied widely from country to country and a one-size-fits-all approach to dementia prevention will not work everywhere, data from 14 countries and regions showed.
Autopsy data from an Alzheimer's patient revealed that brain regions with extensive amyloid clearance after treatment had less downstream tau accumulation and brain degeneration.
A structured multidomain lifestyle intervention may help slow changes in brain white matter associated with aging, a secondary analysis of data from the randomized POINTER trial suggested.
Judy George The FDA approved a new starting dosage regimen for the subcutaneous formulation of lecanemab (Leqembi Iqlik) to treat adults with Alzheimer's disease, the agency said Monday.
